title: The Association of HLA-class I Genes and the Extent of Atherosclerotic Plaques in Patients with Psoriatic Disease.
abstract: To investigate the association between HLA susceptibility and disease severity markers and the extent of atherosclerosis in patients with psoriatic disease.
  
  
  
  White patients with psoriatic arthritis (PsA) and psoriasis without PsA (PsC) were recruited. An ultrasound of the carotid arteries was performed and the size of each atherosclerotic plaque was measured. The resulting score, the total plaque area (TPA), represented the extent of atherosclerosis. HLA genotyping was performed using sequence-specific oligonucleotide probes. The association between 10 HLA susceptibility and severity markers of PsC and PsA and the severity of atherosclerosis was assessed by ordinal logistic regression models adjusted for age, sex, and cardiovascular (CV) risk factors.
  
  
  
  The study involved 411 patients (273 PsA, 138 PsC). Of them, 61.8% had at least 1 atherosclerotic plaque. HLA-B*13:02 and HLA-C*06:02 were associated with more severe atherosclerosis (age- and sex-adjusted OR 2.31, 95% CI 1.23-4.32 and OR 1.68, 95% CI 1.12-2.52, respectively). HLA-B*38:01 was associated with less severe atherosclerosis (OR 0.49, 95% CI 0.28-0.86). These associations remained statistically significant after adjusting for CV risk factors. Higher levels of erythrocyte sedimentation rate (ESR) were associated with more severe atherosclerosis (age- and sex-adjusted OR 1.33, p = 0.02). HLA-B*13:02-positive (p = 0.01) as well as HLA-C*06:02-positive (p = 0.008) patients had higher levels of ESR over time.
  
  
  
  HLA-C*06:02 and B*13:02 alleles are associated with a higher burden of atherosclerosis in patients with psoriatic disease. This association may be mediated by a higher level of systemic inflammation.
authors: From the Women's College Research Institute, Women's College Hospital; the Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, and the Division of Dermatology, Toronto Western Hospital, Toronto, Ontario; and the Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, Ontario, Canada.L. Eder, MD, PhD, Assistant Professor, Clinician Scientist, Women's College Hospital and Division of Rheumatology, Department of Medicine, University of Toronto; F. Abji, MSc, Laboratory Manager, Psoriatic Arthritis Program, Centre for Prognosis Studies in The Rheumatic Diseases, Toronto Western Hospital; C.F. Rosen, MD, Professor, Head of Division of Dermatology, Toronto Western Hospital and University Health Network, Department of Medicine, University of Toronto; V. Chandran, MD, DM, PhD, Assistant Professor, Co-director, Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, and Affiliate Scientist, Krembil Research Institute, and Division of Rheumatology, Department of Medicine, Department of Laboratory Medicine and Pathobiology, University of Toronto; R.J. Cook, PhD, Professor of Biostatistics, Department of Statistics and Actuarial Science, University of Waterloo; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, Senior Scientist, Krembil Research Institute, Director, Psoriatic Arthritis Program, Centre for Prognosis Studies in The Rheumatic Diseases, Toronto Western Hospital.
authors: Lihi
authors: L
authors: Eder
authors: From the Women's College Research Institute, Women's College Hospital; the Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, and the Division of Dermatology, Toronto Western Hospital, Toronto, Ontario; and the Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, Ontario, Canada.L. Eder, MD, PhD, Assistant Professor, Clinician Scientist, Women's College Hospital and Division of Rheumatology, Department of Medicine, University of Toronto; F. Abji, MSc, Laboratory Manager, Psoriatic Arthritis Program, Centre for Prognosis Studies in The Rheumatic Diseases, Toronto Western Hospital; C.F. Rosen, MD, Professor, Head of Division of Dermatology, Toronto Western Hospital and University Health Network, Department of Medicine, University of Toronto; V. Chandran, MD, DM, PhD, Assistant Professor, Co-director, Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, and Affiliate Scientist, Krembil Research Institute, and Division of Rheumatology, Department of Medicine, Department of Laboratory Medicine and Pathobiology, University of Toronto; R.J. Cook, PhD, Professor of Biostatistics, Department of Statistics and Actuarial Science, University of Waterloo; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, Senior Scientist, Krembil Research Institute, Director, Psoriatic Arthritis Program, Centre for Prognosis Studies in The Rheumatic Diseases, Toronto Western Hospital.
authors: Fatima
authors: F
authors: Abji
authors: From the Women's College Research Institute, Women's College Hospital; the Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, and the Division of Dermatology, Toronto Western Hospital, Toronto, Ontario; and the Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, Ontario, Canada.L. Eder, MD, PhD, Assistant Professor, Clinician Scientist, Women's College Hospital and Division of Rheumatology, Department of Medicine, University of Toronto; F. Abji, MSc, Laboratory Manager, Psoriatic Arthritis Program, Centre for Prognosis Studies in The Rheumatic Diseases, Toronto Western Hospital; C.F. Rosen, MD, Professor, Head of Division of Dermatology, Toronto Western Hospital and University Health Network, Department of Medicine, University of Toronto; V. Chandran, MD, DM, PhD, Assistant Professor, Co-director, Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, and Affiliate Scientist, Krembil Research Institute, and Division of Rheumatology, Department of Medicine, Department of Laboratory Medicine and Pathobiology, University of Toronto; R.J. Cook, PhD, Professor of Biostatistics, Department of Statistics and Actuarial Science, University of Waterloo; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, Senior Scientist, Krembil Research Institute, Director, Psoriatic Arthritis Program, Centre for Prognosis Studies in The Rheumatic Diseases, Toronto Western Hospital.
authors: Cheryl F
authors: CF
authors: Rosen
authors: From the Women's College Research Institute, Women's College Hospital; the Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, and the Division of Dermatology, Toronto Western Hospital, Toronto, Ontario; and the Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, Ontario, Canada.L. Eder, MD, PhD, Assistant Professor, Clinician Scientist, Women's College Hospital and Division of Rheumatology, Department of Medicine, University of Toronto; F. Abji, MSc, Laboratory Manager, Psoriatic Arthritis Program, Centre for Prognosis Studies in The Rheumatic Diseases, Toronto Western Hospital; C.F. Rosen, MD, Professor, Head of Division of Dermatology, Toronto Western Hospital and University Health Network, Department of Medicine, University of Toronto; V. Chandran, MD, DM, PhD, Assistant Professor, Co-director, Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, and Affiliate Scientist, Krembil Research Institute, and Division of Rheumatology, Department of Medicine, Department of Laboratory Medicine and Pathobiology, University of Toronto; R.J. Cook, PhD, Professor of Biostatistics, Department of Statistics and Actuarial Science, University of Waterloo; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, Senior Scientist, Krembil Research Institute, Director, Psoriatic Arthritis Program, Centre for Prognosis Studies in The Rheumatic Diseases, Toronto Western Hospital.
authors: Vinod
authors: V
authors: Chandran
authors: From the Women's College Research Institute, Women's College Hospital; the Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, and the Division of Dermatology, Toronto Western Hospital, Toronto, Ontario; and the Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, Ontario, Canada.L. Eder, MD, PhD, Assistant Professor, Clinician Scientist, Women's College Hospital and Division of Rheumatology, Department of Medicine, University of Toronto; F. Abji, MSc, Laboratory Manager, Psoriatic Arthritis Program, Centre for Prognosis Studies in The Rheumatic Diseases, Toronto Western Hospital; C.F. Rosen, MD, Professor, Head of Division of Dermatology, Toronto Western Hospital and University Health Network, Department of Medicine, University of Toronto; V. Chandran, MD, DM, PhD, Assistant Professor, Co-director, Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, and Affiliate Scientist, Krembil Research Institute, and Division of Rheumatology, Department of Medicine, Department of Laboratory Medicine and Pathobiology, University of Toronto; R.J. Cook, PhD, Professor of Biostatistics, Department of Statistics and Actuarial Science, University of Waterloo; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, Senior Scientist, Krembil Research Institute, Director, Psoriatic Arthritis Program, Centre for Prognosis Studies in The Rheumatic Diseases, Toronto Western Hospital.
authors: Richard J
authors: RJ
authors: Cook
authors: From the Women's College Research Institute, Women's College Hospital; the Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, and the Division of Dermatology, Toronto Western Hospital, Toronto, Ontario; and the Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, Ontario, Canada.L. Eder, MD, PhD, Assistant Professor, Clinician Scientist, Women's College Hospital and Division of Rheumatology, Department of Medicine, University of Toronto; F. Abji, MSc, Laboratory Manager, Psoriatic Arthritis Program, Centre for Prognosis Studies in The Rheumatic Diseases, Toronto Western Hospital; C.F. Rosen, MD, Professor, Head of Division of Dermatology, Toronto Western Hospital and University Health Network, Department of Medicine, University of Toronto; V. Chandran, MD, DM, PhD, Assistant Professor, Co-director, Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, and Affiliate Scientist, Krembil Research Institute, and Division of Rheumatology, Department of Medicine, Department of Laboratory Medicine and Pathobiology, University of Toronto; R.J. Cook, PhD, Professor of Biostatistics, Department of Statistics and Actuarial Science, University of Waterloo; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, Senior Scientist, Krembil Research Institute, Director, Psoriatic Arthritis Program, Centre for Prognosis Studies in The Rheumatic Diseases, Toronto Western Hospital. dafna.gladman@utoronto.ca.
authors: Dafna D
authors: DD
authors: Gladman
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D000483:Alleles; D005260:Female; D005805:Genes, MHC Class I / Q000235:genetics*; D056726:Genetic Association Studies; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006239:Haplotypes; D006801:Humans; D008297:Male; D008875:Middle Aged; D058226:Plaque, Atherosclerotic / Q000150:complications / Q000235:genetics* / Q000473:pathology; D011565:Psoriasis / Q000150:complications / Q000235:genetics* / Q000473:pathology; D012720:Severity of Illness Index; D012737:Sex Factors
keywords: ATHEROSCLEROSIS; GENETIC EPIDEMIOLOGY; INFLAMMATION; PSORIATIC DISEASE; ULTRASOUND